Palod Distributors-Home Page
Home Page About Us Products Group Companies Scheme Our Videos Contact Us
News Detail
Mar. 10 2014
Feb 2014.... Industry pegs 4.5%.......Sun continues to shine.....Anti-diabetic
Feb 2014.... Industry pegs 4.5%.......Sun continues to shine.....Anti-diabetic


> you. We are pleased to inform you that we
> have cut down the period of data collection to delivery of
> the data from this month onwards to less than 10 days. Our
> endeavor at AIOCD AWACS has always been to provide you with
> actionable data so that profitable decisions can be taken as
> early as possible & we would continue to streamline our
> processes in the coming months to provide the data within 10
> working days
> As we move toward the new fiscal
> year, the IPM market continues to grow in single digit in
> Feb 2014. -
> H1 list of
> molecules have not been impacted much in the current
> scenario as marginal difference between schedule H1 growth
> rates & industry growth in Feb 14
> -
> Growth in
> the month of Feb 2014 was at 4.5% (-0.2% in existing
> products and 3.2% from new launches). Growth from price
> increase was at 1.5% thereby signifying the impact of price
> cuts witnessed due to the implementation of the pricing
> policy.  -
> The volume
> growths are at 2.6% which are better than the Dec-Feb 2013
> Quarter Volume growths of 0.2%
> -
> The
> Dec– Feb 2014 Qtr has shown positive volume growths as
> compared to the last quarter Sep – Nov 13 -
>
> Major Highlights for
> Month of February 2014: Ø February Month
> Highlights:Ø The IPM clocked 5902 Crs in February
> 2014Ø The Indian Pharma Market grows at
> 4.5% for the month of February 2014
> Ø Corporates:Ø For the month of February 2014,
> amongst the top 10, Sun Pharma grew at 18.1% followed by
> Lupin at 9.3% and Alkem* at 6.7% Ø 29 corporates have crossed the growth
> of IPM for the month of February 2014 amongst top 50
> Ø Amongst the top 50 Corporates, Biocon
> has the highest growth of 46.7% followed by Ajanta at 42.5%
> & Eris at 34.9%Ø Amongst the 11-20 ranked companies
> Aristo shows high growth at 22.4% followed by Torrent at
> 16.6% and Glenmark at 16.3%Ø Sun Pharma becomes the 2nd
> Corporate to enter the 4000 Cr ClubØ Meyer Organics enter the 350 Cr
> Club Ø Indian V/S
> MNCs:Ø Indian companies have grown at 6.9%
> versus -1.7% for MNCs in Feb 2014Ø Amongst the top 50 in MNCs MSD* grew
> the highest at 17.3%, followed by AstraZeneca at 15.3% &
> Merck at 5.1% Ø DPCO
> V/s Non DPCO Market:Ø The DPCO 2013 containing molecules
> market was at –13.6% whereas the non DPCO market grew
> by 7.4% resulting in an overall growth of 4.5% for February
> 2014Ø The DPCO 2013 portfolio for GSK
> degrew at 30.7% & Ranbaxy degrew by 25.2%, whereas Sun
> Pharma had the least impact with its DPCO 2013 portfolio
> degrowing at 6.8% Ø Therapy:Ø From therapy perspective 11 therapies
> have outgrown the IPM growth & 4 therapies have double
> digit growthsØ Respiratory Market grew at
> 6.2%, Gastrointestinal market grew at 5.1% whereas
> Anti-infectives degrew at 0.9%Ø Anti-diabetic market grows at 13.3%
> & Cardiac at 5.9% in chronic businessØ Derma market grew by 12.5%,
>  Ø Regional
> Dynamics:Ø From regional perspective 10 regions
> have outgrown the IPM growthØ Jharkhand market grew the highest at
> 14.0% followed by Vidarbha Market at 13.2%
> Ø 3 regions had negative growths in Feb
> 2014  Ø Molecules:Ø The biggest molecule Amoxycillin +
> Clavulanic degrew by 4.4%, whereas Cefixime degrew at 5.7%.
> Ø The markets of Glimepiride +
> Metformin grew at 33.0%, Protein Supplement by 25.1%,
> Vitamin- D grew by 27.8%, Rosuvastain by 18.9%, Telmisartan
> by 17.6% & Levocetirizine + Montelukast by
> 15.9%
> Ø Brands:Ø Glycomet-GP & Monocef grows at
> 23% amongst the top 10 BrandsØ Amongst the top brands in the IPM,
> Lantus grew by 25%, Skinlite by 19%, Aciloc by 15% amongst
> top 25 Brands Ø New
> Launches in IPM:Ø Total 107 Brands launched in Feb
> 2014Ø Buscogast & Ferinject are the top
> NIs for the month  Therapy Perspective:
> Please note that we have done a
> reprocessing exercise for Albert David, Pharmed, Panacea,
> Pfizer + Wyeth, Corona & Galderma in this
> databaseKindly Note:As
> you are aware from 1st Apr, not only
> majority of Indian Pharma Companies, but also stockiests
> start their new financial year. Considering the same the
> final books of accounts and inventory status of the previous
> year end (31st March) generally gets ready
> by 4th or
> 5th Apr. Considering this factor, we have
> started our monthly data collection in soft copy
> from 5th Apr (Saturday) so that proper data
> can be collected from all
> stockiests. Post verification's the March
> 2014 dataset upload would be delayed by 3-4
> days. Request to kindly bear
> with us for this delay which is beyond our
> control.BR
> Hari
> Natarajan| AIOCD
> Pharmasofttech AWACS Pvt. Ltd
> Vice-President - Business
> Intelligence – India & Global

With Bonus Units at Full Value   Without Bonus Units
Rank MAT Feb -14 Feb-14 Val in Crs Rank MAT Feb -14 Feb-14
MAT MTH Val (Cr) MS% GR% Val (Cr) MS% GR% CORPORATE MAT MTH Val (Cr) MS% GR% Val (Cr) MS% GR%
    75149 100.00 5.9 5902 100.00 4.5 IPM     72236 100.00 6.0 5682 100.00 4.5
1 1 4857 6.46 5.1 385 6.52 3.4 Abbott + Abbott HC + Novo 1 1 4758 6.59 4.6 378 6.66 3.2
2 2 4035 5.37 17.3 333 5.65 18.1 Sun Pharma 2 2 3948 5.47 16.3 324 5.71 16.8
3 3 3743 4.98 5.3 306 5.19 0.6 Cipla 3 3 3493 4.84 8.5 289 5.08 3.4
4 4 3334 4.44 9.9 269 4.56 1.1 Zydus + Biochem 4 4 3116 4.31 9.7 249 4.38 -0.1
5 5 2886 3.84 -0.4 218 3.70 -3.1 Ranbaxy 5 5 2793 3.87 -0.3 211 3.72 -2.7
6 6 2771 3.69 -15.0 207 3.51 -17.5 Glaxo 6 6 2727 3.78 -14.7 205 3.61 -16.5
7 7 2675 3.56 5.3 207 3.50 4.0 Mankind 9 9 2257 3.12 7.6 175 3.08 4.0
8 9 2624 3.49 10.8 195 3.30 6.7 Alkem + Cachet + Indchemie 8 8 2433 3.37 10.1 182 3.20 6.6
9 8 2514 3.35 12.6 204 3.46 9.3 Lupin 7 7 2457 3.40 12.4 200 3.52 9.4
10 10 2198 2.92 3.3 173 2.92 0.0 Pfizer + Wyeth 10 10 2150 2.98 3.0 168 2.96 -0.8
11 11 2112 2.81 15.3 167 2.82 7.7 Emcure + Zuventus 11 11 2048 2.83 15.5 162 2.85 7.8
12 12 1954 2.60 8.4 163 2.76 15.0 Macleods 14 12 1832 2.54 8.1 153 2.70 14.4
13 15 1924 2.56 2.0 142 2.40 -3.7 Sanofi-Aventis + Universal 12 14 1889 2.61 1.7 139 2.44 -4.0
14 13 1885 2.51 9.0 152 2.58 -1.1 Intas 13 13 1863 2.58 8.3 150 2.64 -1.9
15 14 1813 2.41 11.6 143 2.42 22.4 Aristo 15 17 1603 2.22 9.1 127 2.23 19.0
16 16 1619 2.15 16.3 133 2.25 16.3 Glenmark 17 15 1574 2.18 16.0 129 2.27 15.6
17 17 1611 2.14 5.8 129 2.19 5.7 Dr. Reddys 16 16 1580 2.19 4.9 127 2.23 4.8
18 18 1556 2.07 8.9 120 2.03 11.6 Micro + Bal 18 18 1486 2.06 9.4 115 2.02 12.2
19 20 1395 1.86 12.2 108 1.82 1.2 USV 19 20 1388 1.92 12.1 107 1.89 1.1
20 19 1345 1.79 14.5 110 1.87 16.6 Torrent 20 19 1323 1.83 14.5 108 1.90 16.0
21 21 1314 1.75 18.8 105 1.77 24.1 IPCA 21 22 1246 1.72 18.1 100 1.77 24.2
22 22 1200 1.60 -0.5 105 1.77 10.8 Wockhardt 22 21 1176 1.63 -0.7 103 1.81 10.7
23 23 1141 1.52 -0.2 89 1.50 -2.3 Novartis 23 23 1097 1.52 0.1 85 1.50 -1.7
24 24 1028 1.37 10.1 86 1.46 8.1 Alembic 24 24 995 1.38 10.3 83 1.47 9.0
25 27 812 1.08 2.9 59 0.99 5.9 FDC 25 27 790 1.09 2.8 57 1.00 5.5
26 26 767 1.02 6.2 60 1.02 1.2 Unichem 26 26 752 1.04 5.5 59 1.04 0.3
27 25 748 1.00 -0.6 63 1.07 17.3 MSD + Fulford + Organon 27 25 739 1.02 -0.7 62 1.09 17.6
28 28 610 0.81 12.8 49 0.83 15.9 Cadila 28 28 589 0.82 12.7 47 0.84 16.2
29 29 581 0.77 4.5 46 0.78 6.5 Indoco Remedies 29 30 541 0.75 4.7 43 0.75 6.7
30 31 552 0.73 10.9 41 0.69 0.7 Franco 31 31 532 0.74 10.3 39 0.69 0.1
31 30 543 0.72 24.5 46 0.78 34.9 Eris 30 29 540 0.75 24.3 46 0.80 34.7
32 39 529 0.70 -27.0 28 0.48 -48.0 Elder 32 38 504 0.70 -25.7 28 0.49 -45.9
33 32 464 0.62 2.9 36 0.61 4.3 Himalaya 33 32 462 0.64 2.6 36 0.63 3.8
34 33 453 0.60 7.6 34 0.57 5.1 Merck 34 33 443 0.61 6.5 33 0.58 3.7
35 34 417 0.56 0.9 33 0.56 7.0 Blue Cross 37 35 384 0.53 3.6 30 0.53 7.8
36 41 392 0.52 -1.4 28 0.47 -26.1 Bharat Serums 36 39 385 0.53 -1.9 28 0.49 -25.5
37 35 389 0.52 18.5 31 0.53 15.3 Astrazeneca 35 34 385 0.53 17.8 31 0.54 14.3
38 43 380 0.51 -0.6 26 0.43 -4.2 Raptakos, Brett 38 43
eXpert Solution by
North South Technologies Pvt. Ltd.